ライフサイエンスコーパス: acute coronary syndrome

1 n 48 282 consecutive patients with suspected acute coronary syndrome.

2 ls including a total of 52 816 patients with acute coronary syndrome.

3 new cardiac dysfunction, most frequently an acute coronary syndrome.

4 sent in up to 4% of patients presenting with acute coronary syndrome.

5 critical for the prognosis of patients with acute coronary syndrome.

6 cation thresholds in patients with suspected acute coronary syndrome.

7 ly admitted patients, even in the absence of acute coronary syndrome.

8 l infarction in women and men with suspected acute coronary syndrome.

9 e effects of alirocumab on death after index acute coronary syndrome.

10 o alirocumab or placebo 1 to 12 months after acute coronary syndrome.

11 e rapid discharge of patients with suspected acute coronary syndrome.

12 ls and leukocyte activation in patients with acute coronary syndrome.

13 ore definitive studies are needed, including acute coronary syndrome.

14 key molecule associating periodontitis with acute coronary syndrome.

15 tality of alirocumab clinical efficacy after acute coronary syndrome.

16 k of death 6-months after presenting with an Acute Coronary Syndrome.

17 b) trial included participants with a recent acute coronary syndrome.

18 statin therapy in patients stabilized after acute coronary syndrome.

19 ts presenting to EDs with possible emergency acute coronary syndrome.

20 ratification tool in patients with suspected acute coronary syndrome.

21 ely used to evaluate patients with suspected acute coronary syndrome.

22 , reduces cardiovascular events after recent acute coronary syndrome.

23 rdiovascular events (MACE) in the setting of acute coronary syndrome.

24 risk-stratify patients under evaluation for acute coronary syndrome.

25 ay improve cardiac function in patients with acute coronary syndrome.

26 42-0.79) were associated with higher odds of acute coronary syndrome.

27 onary artery disease and 18 046 (56.1%) with acute coronary syndrome.

28 come available on oral P2Y(12) inhibitors in acute coronary syndrome.

29 ation of aspirin, including in patients with acute coronary syndrome.

30 Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome.

31 cardial injury in acute illnesses other than acute coronary syndrome.

32 were interested in studies with data beyond acute coronary syndromes.

33 h autoimmune diseases and causes 2% to 4% of acute coronary syndromes.

34 surface of blood leukocytes in patients with acute coronary syndromes.

35 ance of considering SCAD among patients with acute coronary syndromes.

36 at the highest severity in the continuum of acute coronary syndromes.

37 the current state-of-the-art management for acute coronary syndromes.

38 diabetes mellitus, and 39.7% presented with acute coronary syndromes.

39 a P2Y12 inhibitor has not been assesssed in acute coronary syndromes.

40 nvolved in the pathogenesis of psoriasis and acute coronary syndromes.

41 ving technique, and its use is increasing in acute coronary syndromes.

42 increased propensity to rupture and to cause acute coronary syndromes.

43 y men (73%); age, 63+/-10 years; and 50% had acute coronary syndromes.

44 .3% of patients, and 53% of the patients had acute coronary syndromes.

45 h consisted of both non-ST-segment elevation acute coronary syndrome (14%) and ST-segment elevation m

46 utcomes Network-Get With The Guidelines) for acute coronary syndromes (182,903 patients admitted to 9

47 The most common primary diagnosis was acute coronary syndrome (25%), which consisted of both n

48 Among the 10,004 unique patients, 43.1% had acute coronary syndrome, 46.1% had heart failure, and 12

49 arction (84.4%) and non-ST-segment-elevation acute coronary syndromes (71.5%) than in stable patients

50 Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac trop

51 tudies highlighted treatment disparities for Acute Coronary Syndrome (ACS) among HIV patients.

52 of genetically confirmed FH in patients with acute coronary syndrome (ACS) and compared the diagnosti

53 Patients with acute coronary syndrome (ACS) and concomitant noncoronar

54 Patients with acute coronary syndrome (ACS) and history of coronary ar

55 ta linking cytokines to risk and severity of acute coronary syndrome (ACS) are still limited.

56 se with a low body weight presenting with an acute coronary syndrome (ACS) are unknown.

57 s associated with the long-term prognosis of acute coronary syndrome (ACS) considering depression and

58 YSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocu

59 sessed the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Acc

60 Patients who have had an acute coronary syndrome (ACS) event have an increased ri

61 Increased pre-hospital delay during acute coronary syndrome (ACS) events contributes to wors

62 ristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) events following TAVR.

63 VD categories, namely heart failure (HF) and acute coronary syndrome (ACS) including myocardial infar

64 Acute coronary syndrome (ACS) is a frequent cause of hos

65 ever, its prognostic impact in patients with acute coronary syndrome (ACS) is not well known.

66 percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with or without S

67 isk of subsequent nontarget lesion events in acute coronary syndrome (ACS) patients.

68 Among CVDs, the acute coronary syndrome (ACS) represents the most common

69 e of the inflammatory microRNA, miR-146a, in acute coronary syndrome (ACS) subjects with and without

70 ndothelial cells (ECs) or from patients with acute coronary syndrome (ACS) to promote premature EC ag

71 ng in the unique population of patients with acute coronary syndrome (ACS) treated without percutaneo

72 res apply to the population of patients with acute coronary syndrome (ACS) treated without revascular

73 ted in a significant number of patients with acute coronary syndrome (ACS) using global assays and is

74 r (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin thera

75 Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent des

76 the majority of patients who present with an acute coronary syndrome (ACS), but non-atherosclerotic p

77 F-COAST, a prospective multicenter cohort of acute coronary syndrome (ACS), in relation to BB use: pr

78 ovascular (CV) events in patients with prior acute coronary syndrome (ACS).

79 e the prognostic value of CCL19 and CCL21 in acute coronary syndrome (ACS).

80 y of coronary CTA in patients with suspected acute coronary syndrome (ACS).

81 rrent cardiovascular events in patients with acute coronary syndrome (ACS).

82 iation between polymorphisms of MIF gene and acute coronary syndrome (ACS).

83 SCAD) is an increasingly recognized cause of acute coronary syndromes (ACS) afflicting predominantly

84 about the pathophysiology and mechanisms of acute coronary syndromes (ACS) at the clinical, patholog

85 ith stable ischemic heart disease (SIHD) and acute coronary syndromes (ACS) is unknown.

86 gh-intensity statin therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein

87 ion with adverse prognosis for patients with acute coronary syndromes (ACS).

88 Symptoms remain a poor prompt for acute coronary syndromes (ACS).

89 hed as a guide to treatment in patients with acute coronary syndromes (ACS).

90 clinical manifestations and complications of acute coronary syndromes (ACS).

91 ions, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastroint

92 cific thresholds, in patients with suspected acute coronary syndrome admitted to Swedish coronary car

93 mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular

94 After a recent acute coronary syndrome, alirocumab treatment targeting

95 Among patients with stable angina or an acute coronary syndrome, an iFR-guided revascularization

96 fifty-eight PCI procedures (989 [72.8%] for acute coronary syndrome and 369 [27.2%] for stable angin

97 with elevated risk for recurrent MACE after acute coronary syndrome and a larger absolute and relati

98 c therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary

99 for hs-cTnl identify patients with suspected acute coronary syndrome and at least 2 hours of symptoms

100 es cardiovascular events in patients with an acute coronary syndrome and diabetes.

101 In patients with recent acute coronary syndrome and dyslipidemia despite intensi

102 eline criteria identify patients with recent acute coronary syndrome and dyslipidemia who are at VHR

103 with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipopro

104 lirocumab or placebo in 18 924 patients with acute coronary syndrome and elevated atherogenic lipopro

105 imvastatin in patients hospitalized with the acute coronary syndrome and followed longitudinally post

106 the cornerstone of therapy for patients with acute coronary syndrome and have also been shown to redu

107 reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD.

108 n A-I were associated with increased odds of acute coronary syndrome and its manifestations in indivi

109 ation between WBC and MACE was consistent in acute coronary syndrome and non-acute coronary syndrome

110 with the occurrence of ischemic events after acute coronary syndrome and reduction of those events by

111 tment With Alirocumab), patients with recent acute coronary syndrome and residual dyslipidemia despit

112 rogress on elucidating mechanisms leading to acute coronary syndrome and sudden cardiac death.

113 tients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneou

114 n also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism.

115 with drug-eluting stent implantation for an acute coronary syndrome and were discharged with aspirin

116 Patients (n = 18,924) had a recent acute coronary syndrome and were on high-intensity or ma

117 ebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Int

118 Patients admitted for acute coronary syndrome and/or revascularization, with >

119 ents attending the emergency department with acute coronary syndromes and a reduced number of cardiac

120 y (OR, 1.01; 95% CI, 0.98-1.03; P = .62) for acute coronary syndromes and elective procedures requiri

121 andomly assigned patients who presented with acute coronary syndromes and for whom invasive evaluatio

122 lsalicylic acid monotherapy in patients with acute coronary syndromes and those undergoing percutaneo

123 reduces the risk of PAD events or VTE after acute coronary syndrome, and if such effects are related

124 n for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute panc

125 atients with chronic ischemic heart disease, acute coronary syndromes, and those undergoing percutane

126 who have suffered a non-ST-segment-elevation acute coronary syndrome; and (4) patients with truly sta

127 r Antagonist for Clinical Event Reduction in Acute Coronary Syndrome], and TRILOGY ACS [Platelet Inhi

128 Patients who experience an acute coronary syndrome are at heightened risk of recurr

129 Patients with acute coronary syndrome are at risk for peripheral arter

130 n the diagnosis, management, and outcomes of acute coronary syndrome are well recognized.

131 pass grafts presenting with non-ST elevation acute coronary syndromes are uncertain because these pat

132 riteria included diagnosis of ES, absence of acute coronary syndrome as the arrhythmic trigger, and >

133 r risk were female gender, thrombocytopenia, acute coronary syndrome, atrial fibrillation, congestive

134 TTS, however, differs from an acute coronary syndrome because patients have generally

135 Acute coronary syndromes because of erosion may not requ

136 percutaneous coronary intervention (PCI) or acute coronary syndrome but with increased risk of bleed

137 ould still be considered routinely following acute coronary syndrome, but there is a need for contemp

138 of prasugrel, ticagrelor, and clopidogrel in acute coronary syndrome by a meta-analysis of randomized

139 t initiatives have been developed to improve acute coronary syndrome care largely in high-income coun

140 Incident acute coronary syndrome cases (N=167) were individually

141 ses of erosion points to novel therapies for acute coronary syndrome caused by erosion.

142 In stabilized individuals within 10 days of acute coronary syndrome, combination therapy seemed to b

143 ore frequently with non-ST segment elevation acute coronary syndrome compared with patients without D

144 ques per patient was identified after recent acute coronary syndrome, compared with 2.4+/-2.3 positiv

145 We tested the hypothesis that acute coronary syndromes, coronary interventions, stroke

146 Hospital admissions for acute coronary syndrome declined from mid-February, 2020

147 After acute coronary syndrome, diabetes conveys an excess risk

148 Data about clinical characteristics, acute coronary syndrome diagnosis and treatment, extraco

149 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

150 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

151 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

152 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

153 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

154 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

155 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

156 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

157 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

158 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

159 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

160 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

161 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab

162 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

163 All potential acute coronary syndrome episodes were adjudicated in a b

164 (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00

165 (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE]; NCT00470587

166 (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study [APACE]; NCT00

167 n 10 patients in the first year following an acute coronary syndrome event, despite treatment with th

168 ) inhibitor, in patients stabilized after an acute coronary syndrome event.

169 within 10 days after admission for the index acute coronary syndromes event to either aspirin or riva

170 edian follow-up of 4.8 years, there were 225 acute coronary syndrome events, including 141 MIs and 84

171 n of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes [EVOPACS]; NCT03287609).

172 In acute coronary syndrome, extended-term in comparison wit

173 scular events (including hospitalisation for acute coronary syndrome, fatal myocardial infarction, su

174 he median length of stay among patients with acute coronary syndrome fell from 4 days (IQR 2-9) in 20

175 as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is

176 hospital admissions in England for types of acute coronary syndrome from Jan 1, 2019, to May 24, 202

177 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically

178 n between HDL functional characteristics and acute coronary syndrome has not been investigated compre

179 h a high likelihood of rupture leading to an acute coronary syndrome, have gained great interest in t

180 Troponin in the Evaluation of Patients With Acute Coronary Syndrome [High-STEACS]; NCT01852123).

181 In suspected acute coronary syndrome, high-sensitivity cardiac tropon

182 Furthermore, in patients with acute coronary syndrome, higher neutrophil count on admi

183 or maximum tolerated statin treatment after acute coronary syndrome in 18 924 patients.

184 87.1% were male, the indication for CABG was acute coronary syndrome in 31.3%, and 95.2% of procedure

185 diagnoses (not mutually exclusive) included acute coronary syndrome in 62%, heart failure in 46%, an

186 changes to admissions for different types of acute coronary syndrome in England and to evaluate wheth

187 Patients with an acute coronary syndrome in the preceding 7 to 90 days, t

188 from the ED during evaluation for suspected acute coronary syndrome in the REACH cohort.

189 e screening tests who will be diagnosed with acute coronary syndrome in the subsequent 48 hours.

190 I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjud

191 r investigation of its use for management of acute coronary syndromes in the setting of primary percu

192 als in the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) regi

193 tent among patients who underwent PCI for an acute coronary syndrome, in whom discontinuation of aspi

194 Non-ST-segment elevation acute coronary syndromes include unstable angina and non

195 cardial infarction of unknown type, or other acute coronary syndromes (including unstable angina).

196 n the numbers of admissions for all types of acute coronary syndrome, including both STEMI and NSTEMI

197 oronary artery disease or presenting with an acute coronary syndrome, including ST-segment-elevation

198 management of precipitating factors, such as acute coronary syndrome, infection, or atrial fibrillati

199 Prompt identification of acute coronary syndrome is a challenge in clinical pract

200 Mortality in cardiogenic shock complicating acute coronary syndrome is high, and objective risk stra

201 ertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown.

202 the primary end points of fatal or nonfatal acute coronary syndrome, ischemic stroke, heart failure,

203 versus nonculprit arteries in patients with acute coronary syndrome (median difference: 0.69; interq

204 pioglitazone, in comparison with placebo, on acute coronary syndromes (MI and unstable angina) among

205 Acute coronary syndromes most commonly arise from thromb

206 ts who had been admitted to hospital with an acute coronary syndrome (myocardial infarction or unstab

207 e most common etiology of cardiac arrest was acute coronary syndrome (n = 1,657, 50% of reported).

208 Consecutive patients with suspected acute coronary syndrome (n=48 282) were enrolled in a mu

209 on in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome; NCT00089895).

210 Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800).

211 cy and safety of oral P2Y (12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816

212 The total number of PCIs in patients with no acute coronary syndrome/no prior coronary artery bypass

213 myocardial infarction or biomarker-positive acute coronary syndrome; non-fatal stroke; or cardiovasc

214 gy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardi

215 in two cohorts following a non-ST elevation acute coronary syndrome (NSTE-ACS) event.

216 el in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and planned invasive

217 n [STEMI], n = 399; non-ST-segment elevation acute coronary syndromes [NSTE-ACS], n = 213), whereas t

218 In patients with non-ST-segment elevation acute coronary syndrome (NSTEACS), coronary pathology ma

219 rel presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) in the EARLY ACS (Ear

220 es versus men after non-ST-segment elevation acute coronary syndromes (NSTEACS) or whether difference

221 sive management strategy in non-ST elevation acute coronary syndromes (NSTEACS).

222 was conducted in 18 924 patients with recent acute coronary syndrome on intensive or maximum-tolerate

223 In patients with a recent acute coronary syndrome on optimal statin therapy, aliro

224 be cost-effective in patients with a recent acute coronary syndrome on optimal statin therapy.

225 ease that presents during pregnancy (such as acute coronary syndrome or aortic dissection).

226 On multivariable analysis, acute coronary syndrome or atrial fibrillation trial (ve

227 patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were pl

228 atients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous c

229 re consistent in the subset of patients with acute coronary syndrome or heart failure.

230 tients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y(12) in

231 patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary interve

232 deal duration of the use of aspirin after an acute coronary syndrome or percutaneous coronary interve

233 patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary interve

234 atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary interve

235 emic heart disease, non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardi

236 LRPs are associated with acute coronary syndromes or myocardial infarction, which

237 Is performed in New York in patients without acute coronary syndromes or previous coronary artery byp

238 risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarcti

239 andomized participants with non-ST-elevation acute coronary syndromes or stable angina and to evaluat

240 5% CI, 0.96-1.03; P = .65), non-ST-elevation acute coronary syndrome (OR, 0.99; 95% CI, 0.93-1.05; P

241 rapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is ma

242 We randomized 160 acute coronary syndrome patients at 4 Veterans Affairs c

243 of short-term mortality and complications in acute coronary syndrome patients treated with extracorpo

244 usion criteria were observational studies on acute coronary syndrome patients treated with extracorpo

245 LDL apheresis in nonfamilial hyperlipidemia acute coronary syndrome patients treated with percutaneo

246 LDL apheresis in nonfamilial hyperlipidemia acute coronary syndrome patients treated with percutaneo

247 ntaneous adhesion of CD28(null) T cells from acute coronary syndrome patients, and calcium ionophores

248 before operating on P2Y12 inhibitor-treated acute coronary syndrome patients, to allow dissipation o

249 In a multicenter trial, non-ST elevation acute coronary syndromes patients with prior coronary ar

250 s noninvasive management in non-ST elevation acute coronary syndromes patients with prior coronary ar

251 In patients hospitalized with acute coronary syndrome, plasmatic serotonin levels corr

252 aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, o

253 Troponin in the Evaluation of Patients With Acute Coronary Syndrome) population (<5 ng/L at presenta

254 onsistent in acute coronary syndrome and non-acute coronary syndrome presentations (interaction P=0.1

255 hs-cTnT protocol in patients with suspected acute coronary syndrome presenting to the emergency depa

256 d develop point-of-care tests to distinguish acute coronary syndromes provoked by erosion versus rupt

257 m November 2014 to November 2016 through the Acute Coronary Syndrome Quality Improvement in Kerala ra

258 ong 1261 participants in the ACS QUIK trial (Acute Coronary Syndrome Quality Improvement in Kerala).

259 and nonrandomized studies for hospital-based acute coronary syndrome quality improvement intervention

260 Hospital-based acute coronary syndrome quality improvement intervention

261 grams have an ongoing and important role for acute coronary syndrome quality of care in high-income c

262 ients with stable coronary artery disease or acute coronary syndrome randomly assigned to treatment w

263 to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemi

264 le atherosclerosis, atrial fibrillation, and acute coronary syndrome), region of patient enrollment,

265 t beyond clinical variables in patients with acute coronary syndrome-related cardiogenic shock and ma

266 eness in statin-treated patients with recent acute coronary syndrome remains uncertain.

267 atory index values were marginally linked to acute coronary syndrome risk (OR(1SD), 1.27; 95% CI, 0.9

268 In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related t

269 .69-1.04]; P=0.11); non-ST-segment-elevation acute coronary syndrome (RR, 0.84 [95% CI, 0.72-0.97]; P

270 recruiting 185 614 participants with either acute coronary syndrome, stable CHD, or a mixture of bot

271 ion before randomisation), for patients with acute coronary syndromes started within 10 days after pr

272 i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failur

273 scular death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revasculari

274 son of Prasugrel [CS-747] and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Perc

275 and 1-month post-discharge 1521 nondemented acute coronary syndrome survivors enrolled in TRACE (Tra

276 nt of patients with non-ST-segment elevation acute coronary syndrome, the optimal timing of their adm

277 g and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical tr

278 alization with worsening of heart failure or acute coronary syndrome; the second primary outcome was

279 ify the Optimal Strategy to Medically Manage Acute Coronary Syndromes]), the association between post

280 ging from 2.0 (95% CI, 1.5-2.8; P<0.001) for acute coronary syndrome to 13.0 (95% CI, 9.4-18.1; P<0.0

281 sment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study between Ap

282 on in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome) trial.

283 ing Computerized Tomography in Patients With Acute Coronary Syndromes) trial (NCT02061891) evaluated

284 Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-d

285 es in patients with non-ST-segment elevation acute coronary syndrome undergoing invasive treatment.

286 ssociation included increased age, male sex, acute coronary syndrome, valvular disease, carotid disea

287 ify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) was a double-blind, placebo-co

288 Consecutive patients with suspected acute coronary syndrome were enrolled in a stepped-wedge

289 because of stable coronary artery disease or acute coronary syndrome were included from the nationwid

290 Patients who experienced acute coronary syndrome were randomized to a placebo/sim

291 ,098 unselected all-comer patients (50% with acute coronary syndrome) were randomly assigned to have

292 tients, with or without ST-segment elevation acute coronary syndrome, were randomly assigned to radia

293 aluation of Cardiovascular Outcomes After an Acute Coronary Syndrome), which was conducted in 18 924

294 f 2037 participants with stable angina or an acute coronary syndrome who had an indication for physio

295 in acutely admitted patients with suspected acute coronary syndrome who had been discharged without

296 ction in the weekly numbers of patients with acute coronary syndrome who were admitted to hospital in

297 COVID-19 on the management of patients with acute coronary syndrome will continue to be assessed by

298 The TAO trial (Treatment of Acute Coronary Syndrome With Otamixaban) randomized pati

299 P2Y(12) Receptor Blockers In Non-ST Elevated Acute Coronary Syndromes With Initial Invasive Indicatio

300 Among patients who presented with acute coronary syndromes with or without ST-segment elev

301 ded fatal or nonfatal myocardial infarction, acute coronary syndrome without myocardial infarction, c